Business · 23/11/2022Updated: 10/17/2026 · 1 min read
Bristol Myers Products Inc. Faces FDA Proposal to Withdraw Approval of Bufferin (Aspirin) Tablets
Summary
The FDA is proposing to withdraw approval of a new drug application for Bufferin (aspirin) tablets due to repeated failure to file required annual reports, and Bristol Myers Products Inc. is given the opportunity to request a hearing on the proposal.